Coenzyme Q10
Of 3,254 on-market coenzyme q10 products in the January 2026 DSLD dump, the median declared dose is 60 mg, and 97.6% list Ubiquinone (oxidized form) as the primary form.
Form share
Of 3,247 products with an identifiable primary form, here is the share held by each form of Coenzyme Q10 on the market today.
| Form | Quality tier | n | Share |
|---|---|---|---|
| Ubiquinone (oxidized form) | Tier 2 | 3,170 | 97.6% |
| Ubiquinol (reduced/active form) | Tier 1 | 77 | 2.4% |
Form share over time
Entry-year breakdown of the top forms, 2012–2025.
Dose distribution
Deciles of declared dose per serving (mg), among 2,757 products with a disclosed amount.
- 19.6% of products fall below the fairy-dust threshold (20 mg, 20% of the studied low dose).
- 12.8% of products don't disclose an amount because Coenzyme Q10 is declared inside a proprietary blend.
By dosage form
By target group
Top brands
Forms explained
Standard/most common commercial form but achieves lower plasma AUC than ubiquinol at equal dose, particularly as ubiquinone-to-ubiquinol conversion efficiency declines with age.
Source: Langsjoen PH, Langsjoen AM. 2014, Clin Pharmacol Drug Dev 3(1):13-17, PMID 27128225
Achieved ~1.7x higher plasma concentration than ubiquinone at an equal 200mg/day dose in direct comparison (other studies report 2-4.3x higher AUC, especially in the elderly).
Source: Langsjoen PH, Langsjoen AM. 2014, PMID 27128225
Reference values
- RDA (adult): not established — Endogenously synthesized; not classified as an essential nutrient. No NIH ODS fact sheet, RDA, or AI exists.
- Tolerable Upper Intake Level (adult): not established — Not established as a formal UL. Hidaka T et al. safety review (PMID 19096117) found no significant adverse effects up to 1200mg/day across trials (typical trial doses 100-200mg/day); a 52-week rat NOAEL of 1200mg/kg/day yields a calculated ADI of ~720mg/day for a 60kg adult. Doses up to 1200-3600mg/day have been used short-term in neurodegenerative-disease trials and tolerated -- not the same as a population UL.
- Studied clinical dose range: 100–300 mg
- Mortensen SA et al. 2014 (Q-SYMBIO trial), JACC Heart Fail 2(6):641-649 -- 100mg TID (300mg/day) x2yr reduced all-cause mortality in moderate-severe heart failure (9% vs 17%, HR~0.5, P=.01). Also Sandor PS et al. 2005, Neurology 64(4):713-5, PMID 15728298 -- 300mg/day significantly reduced migraine frequency vs placebo.